Fimasartan

Generic Name: Fimasartan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₁N_₇OS

CAS Number: 247257-48-3

Unique Ingredient Identifier: P58222188P

Background: Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.

Indication: Used for the treatment of hypertension and heart failure .

Associated Conditions: Hypertension, Essential Hypertension

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Phase 3

Completed

Conditions: Essential Hypertension
Primary Hypercholesterolemia

Interventions: Drug: Fimasartan
Drug: Ezetimibe/Atorvastatin
Drug: Ezetimibe/Atorvastatin Placebo
Drug: Fimasartan Placebo

First Posted Date: 2023-07-05

Last Posted Date: 2024-10-18

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 148

Registration Number: NCT05930028

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension

Phase 4

Recruiting

Conditions: Atherosclerosis
Diabetes Mellitus, Type 2
Renin Hypertension
Hypertension

Interventions: Drug: Fimasartan

First Posted Date: 2021-12-29

Last Posted Date: 2023-08-14

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 42

Registration Number: NCT05173025

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

Completed

Conditions: Left Ventricular Hypertrophy
Hypertension

First Posted Date: 2017-07-17

Last Posted Date: 2017-07-17

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 72

Registration Number: NCT03219632

Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan

Phase 4

Conditions: Hypertension

Interventions: Drug: Fimasartan
Drug: Losartan

First Posted Date: 2016-11-08

Last Posted Date: 2016-11-08

Lead Sponsor: Chuncheon Sacred Heart Hospital

Target Recruit Count: 40

Registration Number: NCT02958631

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Fimasartan
Drug: Rosuvastatin
Drug: Fimasartan + Rosuvastatin

First Posted Date: 2016-03-10

Last Posted Date: 2018-11-02

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT02704702

A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet

Phase 1

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: Fimasartan/Atorvastatin Combination Tablet
Drug: Fimasartan
Drug: Atorvastatin

First Posted Date: 2015-10-02

Last Posted Date: 2016-02-25

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 99

Registration Number: NCT02566187

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Fimasartan Achieving SBP Target (FAST) Study

Phase 4

Completed

Conditions: Essential,Hypertension

Interventions: Drug: Placebo
Drug: Valsartan
Drug: Fimasartan
Drug: Olmesartan medoxomil

First Posted Date: 2015-07-13

Last Posted Date: 2017-07-05

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 369

Registration Number: NCT02495324

Locations: 🇰🇷
The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
🇰🇷
The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of

and more 5 locations

Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension, Essential

Interventions: Drug: Fimasartan; Hydrochlorothiazide
Drug: Fimasartan

First Posted Date: 2015-06-09

Last Posted Date: 2015-06-09

Lead Sponsor: Stendhal Americas, S.A.

Target Recruit Count: 272

Registration Number: NCT02466490

Locations: 🇲🇽
Centro Médico Exel, Tijuana, Baja California, Mexico
🇲🇽
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
🇲🇽
Unidad de Investigación Clínica Cardiometabólica de Occidente, Guadalajara, Jalisco, Mexico

and more 10 locations

Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Phase 4

Conditions: Blood Pressure
Ischemic Stroke

Interventions: Drug: Fimasartan
Drug: Valsartan
Drug: Atenolol

First Posted Date: 2015-03-31

Last Posted Date: 2015-03-31

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 105

Registration Number: NCT02403349

Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Fimasartan
Drug: Amlodipine
Drug: Rosuvastatin

First Posted Date: 2015-03-25

Last Posted Date: 2015-07-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 50

Registration Number: NCT02397538

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy